Newsroom | 9778 results

AMSTERDAM--(BUSINESS WIRE)--Royal Philips (NYSE: PHG, AEX: PHIA), een wereldwijde marktleider op het gebied van gezondheidstechnologie, en Imricor Medical Systems (ASX: IMR), een pionier en toonaangevende ontwikkelaar van MR-compatibele producten voor interventionele MR-procedures, hebben vandaag een nieuwe laboratoriumoplossing voor interventionele MR (iMR) aangekondigd voor de 1,5T MR-scanners van Philips. Deze eerste commercieel beschikbare configuratie combineert het 1,5T MRI-platform van P...

ÁMSTERDAM--(BUSINESS WIRE)--Royal Philips (NYSE: PHG, AEX: PHIA), líder mundial en tecnología sanitaria, e Imricor Medical Systems (ASX: IMR), empresa pionera y líder mundial en el desarrollo de productos compatibles con RM para procedimientos intervencionistas guiados por RM, han anunciado hoy una nueva solución de RM intervencionista (iMR) para los equipos de RM de 1,5 T de Philips. La primera configuración disponible comercialmente combina la plataforma de RM de 1,5 T de Philips con la carte...

AMSTERDAM--(BUSINESS WIRE)--Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for ca...

VANCOUVER, British Columbia--(BUSINESS WIRE)--The Government of Canada today announced funding of up to $31.25 million through the Strategic Response Fund (SRF) toward Kardium’s investment in a $125 million project to expand its manufacturing capabilities in Vancouver, British Columbia. The announcement was made by the Honourable Mélanie Joly, Minister of Industry and Minister responsible for Canada Economic Development for Quebec Regions. The investment will support a major expansion of Kardiu...

MEMPHIS, Tenn.--(BUSINESS WIRE)--This September, supporters across the country will rally behind St. Jude Children's Research Hospital®, joining a nationwide movement to raise awareness and funds for children with cancer and other life-threatening diseases. “While children and families face childhood cancer every day, Childhood Cancer Awareness Month is an important opportunity to shine a light on the challenges they endure and how they are counting on us to accelerate progress,” said Ike Anand...

MIAMI & LEAWOOD, Kan.--(BUSINESS WIRE)--The American Medical Society for Sports Medicine (AMSSM) and OpenEvidence today announced a partnership that will focus on co-developing AI-powered educational resources on sports medicine for both patients and clinicians. This exclusive collaboration brings the expertise of AMSSM’s sports medicine physicians to OpenEvidence, the leading AI-powered clinical decision support platform, and will build on the AMSSM’s robust foundation of educational materials....

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced its fiscal 2026 third quarter results for the period ended June 30, 2026. Full financial statements and management’s discussion and analysis are available on the Company’s profile at www.sedarplus.ca. Brent Ashton, Covalon’s Chief Executive Officer, commented, “Covalon’s third quarter of fiscal 2026 delivered outstandi...

LONDRES--(BUSINESS WIRE)--VirTus Respiratory Research Ltd, una organización especializada en investigación por contrato (CRO) en el ámbito respiratorio, fundada por los investigadores del Imperial College de Londres, el profesor Sebastian Johnston y el doctor Michael Edwards, ha destacado hoy su papel en el desarrollo preclínico del APL-10456 de Apollo Therapeutics y el Imperial, tras el anuncio de los datos iniciales positivos del ensayo clínico de fase I de la vacuna. VirTus ha trabajado en e...

LONDEN--(BUSINESS WIRE)--VirTus Respiratory Research Ltd, een CRO (contract research organisation) gespecialiseerd in geneesmiddelen voor de luchtwegen opgericht door professor Sebastian Johnston en Dr. Michael Edwards, onderzoekers van de Imperial College London, belichtte vandaag de rol van de organisatie in de preklinische ontwikkeling van Apollo Therapeutics’ en Imperial’s APL-10456, na de aankondiging van positieve eerste gegevens uit de Fase 1 klinische studie van het vaccin. VirTus werkt...

LONDRA--(BUSINESS WIRE)--VirTus Respiratory Research Ltd, un'organizzazione di ricerca a contratto (CRO) specializzata in patologie respiratorie fondata dal professor Sebastian Johnston e dal Dr. Michael Edwards, ricercatori dell'Imperial College London, oggi ha sottolineato il proprio ruolo nello sviluppo preclinico di APL-10456, di Apollo Therapeutics e dell'Imperial College, a seguito dell'annuncio relativo ai dati iniziali positivi relativi alla fase 1 della sperimentazione clinica sul vacc...